Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cholinesterases: Distribution and Function01:22

Cholinesterases: Distribution and Function

1.2K
Cholinesterases are a group of serine hydrolase enzymes that play a crucial role in the breakdown of choline esters. The two primary types of cholinesterases are acetylcholinesterases (AChEs) and butyrylcholinesterase (BuChEs), which differ in their distribution, function, and substrate specificity. AChEs, also known as true cholinesterases, specifically hydrolyze acetylcholine, while BuChEs, often referred to as pseudocholinesterases, can hydrolyze various choline esters, including...
1.2K
Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

1.9K
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
1.9K
Indirect-Acting Cholinergic Agonists: Mechanism of Action01:18

Indirect-Acting Cholinergic Agonists: Mechanism of Action

3.0K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
3.0K
Indirect-Acting Cholinergic Agonists: Pharmacokinetics01:22

Indirect-Acting Cholinergic Agonists: Pharmacokinetics

1.7K
Indirect-acting cholinergic agonists, or anticholinesterases, enhance the body's cholinergic activity by inhibiting acetylcholine's breakdown. They are categorized as reversible or irreversible agents based on their mechanism of action. They are further classified into short-acting, intermediate-acting, and long-acting agents based on their duration of action.
Reversible agents containing quaternary amines, such as neostigmine and edrophonium, are not easily absorbed orally because they...
1.7K
Indirect-Acting Cholinergic Agonists: Pharmacological Actions01:30

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

1.8K
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
1.8K
Chemical Synapses01:26

Chemical Synapses

12.4K
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
12.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Essential laboratory tests in emergencies; on behalf of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Committee on Preparation of Laboratories for Emergencies (C-PLE).

Clinical chemistry and laboratory medicine·2026
Same author

French-Speaking Network of Pharmacogenetics (RNPGx) Recommendations for Gene Panel Analysis Through Genotyping or Sequencing in Pharmacogenetics.

Fundamental & clinical pharmacology·2026
Same author

The risk of secondary exposure in the operating room from a sulfur mustard-contaminated penetrating wound using a simulation scenario.

Clinical toxicology (Philadelphia, Pa.)·2025
Same author

[Appropriateness of prescribing injectable iron: A single-center retrospective study in a hospital setting].

La Revue de medecine interne·2025
Same author

Diagnostic performance of adenosine deaminase for extrapulmonary tuberculosis in a higher-prevalence area of mainland France: a 10-year retrospective study.

Infection·2025
Same author

Pharmacogenetics testing for poor response to antidepressants: a transnosographic case series.

Frontiers in pharmacology·2024

Related Experiment Video

Updated: Mar 20, 2026

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
10:16

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

Published on: December 20, 2017

8.6K

Butyrylcholinesterase deficiency.

Hervé Delacour1, Emmanuel Dedome1, Sébastien Courcelle1

  • 1Hôpital d'instruction des armées Bégin, Fédération de biologie clinique, Saint-Mandé, France.

Annales De Biologie Clinique
|May 31, 2016
PubMed
Summary
This summary is machine-generated.

Butyrylcholinesterase (BChE) deficiency, often caused by BCHE gene mutations, can lead to prolonged apnea, particularly with the rs1799807 variant. This enzyme is crucial for drug metabolism and anesthetic response.

Keywords:
butyrylcholinesterasebutyrylcholinesterase deficiencymivacuriumsuxamethonium

More Related Videos

The Neuromuscular Junction: Measuring Synapse Size, Fragmentation and Changes in Synaptic Protein Density Using Confocal Fluorescence Microscopy
12:18

The Neuromuscular Junction: Measuring Synapse Size, Fragmentation and Changes in Synaptic Protein Density Using Confocal Fluorescence Microscopy

Published on: December 26, 2014

22.9K
In Vivo Electrophysiological Measurement of Compound Muscle Action Potential from the Forelimbs in Mouse Models of Motor Neuron Degeneration
06:35

In Vivo Electrophysiological Measurement of Compound Muscle Action Potential from the Forelimbs in Mouse Models of Motor Neuron Degeneration

Published on: June 15, 2018

20.9K

Related Experiment Videos

Last Updated: Mar 20, 2026

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
10:16

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

Published on: December 20, 2017

8.6K
The Neuromuscular Junction: Measuring Synapse Size, Fragmentation and Changes in Synaptic Protein Density Using Confocal Fluorescence Microscopy
12:18

The Neuromuscular Junction: Measuring Synapse Size, Fragmentation and Changes in Synaptic Protein Density Using Confocal Fluorescence Microscopy

Published on: December 26, 2014

22.9K
In Vivo Electrophysiological Measurement of Compound Muscle Action Potential from the Forelimbs in Mouse Models of Motor Neuron Degeneration
06:35

In Vivo Electrophysiological Measurement of Compound Muscle Action Potential from the Forelimbs in Mouse Models of Motor Neuron Degeneration

Published on: June 15, 2018

20.9K

Area of Science:

  • Biochemistry
  • Pharmacology
  • Genetics

Background:

  • Butyrylcholinesterase (BChE) is an enzyme structurally related to acetylcholinesterase.
  • While lacking clear physiological roles, BChE is vital for detoxifying ester-containing drugs and influences responses to muscle relaxants like suxamethonium and mivacurium.
  • BChE deficiency primarily results from mutations in the BCHE gene, with over 70 documented human variants impacting enzyme activity or expression.

Purpose of the Study:

  • To investigate the toxicological and pharmacological significance of Butyrylcholinesterase (BChE).
  • To understand the genetic basis of BChE deficiency and its clinical implications.
  • To identify specific BCHE gene mutations associated with adverse drug reactions and prolonged apnea.

Main Methods:

  • Literature review of BChE function, genetics, and clinical cases.
  • Analysis of documented BCHE gene mutations and their effects on enzyme activity.
  • Examination of the association between BChE deficiency variants and patient outcomes, particularly prolonged apnea.

Main Results:

  • BChE plays a critical role in drug metabolism and is essential for normal responses to certain muscle relaxants.
  • BChE deficiency, mainly caused by BCHE gene mutations, leads to asymptomatic individuals except for heightened sensitivity to BChE-metabolized drugs.
  • The rs1799807 variant of the BCHE gene is frequently implicated in prolonged apnea following exposure to BChE substrates.

Conclusions:

  • Mutations in the BCHE gene are the primary cause of BChE deficiency, affecting enzyme function and expression.
  • BChE deficiency has significant pharmacological implications, particularly concerning anesthetic drug safety.
  • The rs1799807 variant represents a key genetic factor contributing to prolonged apnea in susceptible individuals.